

False-positive cardiac troponin T due to assay interference with heterophilic antibodies

Noushin Shayanfar^a, Lukas Bestmann^a, Georg Schulthess^b, Martin Hersberger^c

^a Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland

^b Medical Policlinic, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland

^c Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zürich, Zurich, Switzerland

A 38-year-old woman was admitted to the emergency unit with chest pain radiating to her left arm. She had recently suffered from a cold with cough and neck pain lasting for 2 weeks. The patient had a history of deep venous thrombosis during pregnancy associated with APC-resistance. She had neither cardiovascular risk factors nor a history of coronary or cerebral artery disease. The family history was negative for coronary heart disease and stroke.

On admission the patient complained of strong pain in the left side of the chest worsening on inspiration. She had painful musculoskeletal points on the left chest wall and neck, otherwise physical examination was normal. Computed tomography of the chest ruled out pulmonary embolism. Neither electrocardiogram nor echocardiography showed any evidence of perimyocarditis, myocardial ischaemia or cardiac infarction. However, elevated troponin T serum levels (1.76 µg/l) were detected (Elecsys E170, Roche Diagnostic, Rotkreuz, Switzerland), while CK (90 U/l, Modular P, Roche Diagnostic), CK-MB (13 U/l, Modular P, Roche Diagnostic), and myoglobin (29 U/l, Elecsys E170, Roche Diagnostic) were within reference ranges.

Repeat measurements showed that serum concentration of troponin T remained elevated (1.65 µg/l, 1.46 µg/l and 1.75 µg/l after two, six and 48 hours, respectively) while levels of CK, CK-MB, and myoglobin remained within their reference ranges.

In view of the persistently elevated serum concentrations of troponin T without elevation of other cardiac necrosis markers, we decided not to undertake coronary angiography suspecting interference of heterophilic antibodies with the troponin T assay. To show such interference, we treated a serum sample of our patient with heterophilic blocking reagent (Scantibodies Laboratory, Santee, CA, USA) for one hour and measured troponin T again. The troponin T level decreased to 0.18 µg/l upon treatment with the blocking antibody while the same treatment did not alter the troponin T level in a sample from a patient with acute coronary syndrome measured in parallel. These results confirmed antibody interference in the troponin assay. The patient was discharged with the diagnosis of musculoskeletal chest pain.

The origin of the heterophilic antibodies is not clear. However, in a recent review Levinson and Miller argued that they represent natural antibodies that bind their antigen with low affinity [1]. This may explain why the older radioimmunoassay that depend on strong affinity binding of the antibodies were less prone to such interactions than the newer generation immunoassays [1]. These modern immunoassays have been revised by adding non-specific blocking antibodies to the assay to reduce the effect of interfering antibodies [2], however, some patients may exceed the blocking capacity of a specific immunoassay procedure [3, 4].

It is estimated that heterophilic antibodies cause about one false result in every 2000 investigations produced with modern immunoassays [1]. This can result in unnecessary and possibly even harmful diagnostic procedures and/or treatment. Therefore, physicians need to be aware of these interferences with immunoassays, which basically can occur with every immunoassay. Contacting their laboratory directors will allow

testing for the presence of such heterophilic antibodies in a patient's sample. The suspected sample can be re-measured with an assay from another manufacturer and will usually give a discordant result, at least when assayed by a different two-site method [1]. Alternatively, the sample can be re-analyzed after pre-treatment with commercially available heterophilic blocking reagents, as presented in this report [5, 6].

Correspondence:

Martin Hersberger
Division of Clinical Chemistry
and Biochemistry
University Children's Hospital Zürich
Steinwiesstrasse 75
CH-8032 Zürich
Switzerland
E-Mail: martin.hersberger@kispi.uzb.ch

References

- 1 Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. [see comment]. *Clin Chim Acta.* 2002;325(1-2): 1-15.
- 2 Yeo KT, et al. Performance of the enhanced Abbott AxSYM cardiac troponin I reagent in patients with heterophilic antibodies. *Clin Chim Acta.* 2000;292(1-2):13-23.
- 3 Klee GG. Human anti-mouse antibodies. *Archives of Pathology & Laboratory Medicine.* 2000;124(6):921-3.
- 4 Kim WJ, et al. Performance of a revised cardiac troponin method that minimizes interferences from heterophilic antibodies. *Clin Chemistry.* 2002;48(7):1028-34.
- 5 Preissner CM, et al. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. *Clin Chemistry.* 2005;51(1):208-10.
- 6 Trojan A, et al. False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer. *Oncology.* 2004;66(4):336-8.

SMW

Established in 1871
Formerly: Schweizerische Medizinische Wochenschrift
Swiss Medical Weekly

The European Journal of Medical Sciences

The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW's impact factor has been steadily rising. The 2006 impact factor is 1.346.
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website <http://www.smw.ch> (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of professional statisticians for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing

Editorial Board

Prof. Jean-Michel Dayer, Geneva
Prof Paul Erne, Lucerne
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(editor in chief)
Prof. Werner Straub, Berne (senior editor)
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:

http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: <http://www.smw.ch>